6,10-dihydroxybuspirone | 658701-59-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6,10-dihydroxybuspirone
• 英文别名: 6,10-Dihydroxy Buspirone；6,10-dihydroxy-8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione
• CAS: 658701-59-8
• 化学式: C₂₁H₃₁N₅O₄
• 分子量: 417.508
• InChiKey: GZDZGTXOYYJHTI-UHFFFAOYSA-N

物化性质

• 熔点：
  190-194°C
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.03
• 重原子数：
  30.0
• 可旋转键数：
  6.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  110.1
• 氢给体数：
  2.0
• 氢受体数：
  8.0

反应信息

• 作为产物：
  描述：

  丁螺环酮 在 sodium hexamethyldisilazane 、 亚磷酸三乙酯 作用下， 以 四氢呋喃 为溶剂， 以71%的产率得到6-羟基-8-[4-(嘧啶-2-基)-1-哌嗪基丁基]-8-氮杂螺[4,5]癸烷-7,9-二酮
  参考文献：
  名称：

  Development of a Safe and Scalable Oxidation Process for the Preparation of 6-Hydroxybuspirone:  Application of In-Line Monitoring for Process Ruggedness and Product Quality

  摘要：

  The development of a safe and scalable oxidation process for the hydroxylation of the azapirone psychotropic agent buspirone (1) to furnish 6-hydroxybuspirone (2) is described. A mechanistic understanding of how key process factors affected product quality led to the successful application of FTIR as a process analytical technology (PAT) tool. This enabled real time quality assurance and the development of an effective and efficient manufacturing process. The identification of impurities and the development of recrystallization methods to provide active pharmaceutical ingredients (API) with optimal purity will also be addressed.

  DOI：

  10.1021/op049918r

文献信息

• Development of a Safe and Scalable Oxidation Process for the Preparation of 6-Hydroxybuspirone:  Application of In-Line Monitoring for Process Ruggedness and Product Quality
  作者：Daniel J. Watson、Eric D. Dowdy、Jeffrey S. DePue、Atul S. Kotnis、Simon Leung、Brian C. O'Reilly

  DOI：10.1021/op049918r

  日期：2004.7.1

  The development of a safe and scalable oxidation process for the hydroxylation of the azapirone psychotropic agent buspirone (1) to furnish 6-hydroxybuspirone (2) is described. A mechanistic understanding of how key process factors affected product quality led to the successful application of FTIR as a process analytical technology (PAT) tool. This enabled real time quality assurance and the development of an effective and efficient manufacturing process. The identification of impurities and the development of recrystallization methods to provide active pharmaceutical ingredients (API) with optimal purity will also be addressed.